Fig. 1. Impact of fibroblast growth factor 21 (FGF21) on diabetes-induced general changes and on renal function. Four-month-old female transgenic type 1 diabetes mellitus (DM) (FVB [Cg]-Tg [Cryaa-Tag, Ins2-CALM1] 26OVE/PneJ [OVE26]) mice and Friend Virus B NIH Jackson (FVB/NJ) control mice were given FGF21 (100 µg/kg) or an equal volume of phosphate-buffered saline (PBS) daily for 3 months (A). Weekly body weight before sacrifice (B), weekly blood glucose before sacrifice (C), urinary albumin (D), glomerular filtration rate (GFR) (E), survival rate (F), kidney weight to tibia length ratio (G), and plasma FGF21 (H) were examined. Data are presented as mean±standard deviation (Friend virus B NIH Jackson [FVB], n=9; diabetes mellitus [DM], n=10; FGF21-treated diabetic mice [FGF21], n=6). i.p., intraperitoneally; UA, urine albumin. aP≤0.05 for each DM vs. FVB/NJ groups, bP≤0.05 for DM/FGF21 vs. DM groups.
